News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
566,436 Results
Type
Article (35013)
Company Profile (115)
Press Release (531308)
Multimedia
Podcasts (46)
Webinars (11)
Section
Business (163556)
Career Advice (1377)
Deals (29460)
Drug Delivery (90)
Drug Development (63592)
Employer Resources (97)
FDA (14701)
Job Trends (12584)
News (278658)
Policy (27691)
Tag
Academia (2253)
Accelerated approval (4)
Adcomms (16)
Allergies (80)
Alliances (41470)
ALS (76)
Alzheimer's disease (1160)
Antibody-drug conjugate (ADC) (85)
Approvals (14718)
Artificial intelligence (236)
Autoimmune disease (18)
Automation (12)
Bankruptcy (278)
Best Places to Work (10231)
BIOSECURE Act (14)
Biosimilars (60)
Biotechnology (70)
Bladder cancer (74)
Brain cancer (23)
Breast cancer (255)
Cancer (2027)
Cardiovascular disease (159)
Career advice (1191)
Career pathing (21)
CAR-T (129)
Cell therapy (367)
Cervical cancer (20)
Clinical research (52808)
Collaboration (713)
Compensation (385)
Complete response letters (15)
COVID-19 (2063)
CRISPR (30)
C-suite (224)
Cystic fibrosis (77)
Data (2084)
Decentralized trials (2)
Denatured (24)
Depression (39)
Diabetes (240)
Diagnostics (5683)
Digital health (17)
Diversity (9)
Diversity, equity & inclusion (24)
Drug discovery (97)
Drug pricing (100)
Drug shortages (28)
Duchenne muscular dystrophy (81)
Earnings (63330)
Editorial (38)
Employer branding (10)
Employer resources (82)
Events (78638)
Executive appointments (695)
FDA (15980)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (640)
Gene editing (82)
Generative AI (20)
Gene therapy (254)
GLP-1 (590)
Government (4109)
Grass and pollen (5)
Guidances (124)
Healthcare (17242)
Huntington's disease (14)
IgA nephropathy (23)
Immunology and inflammation (79)
Indications (25)
Infectious disease (2185)
Inflammatory bowel disease (126)
Inflation Reduction Act (7)
Influenza (44)
Intellectual property (84)
Interviews (190)
IPO (13520)
IRA (37)
Job creations (2728)
Job search strategy (1036)
Kidney cancer (8)
Labor market (29)
Layoffs (277)
Leadership (10)
Legal (5977)
Liver cancer (67)
Lung cancer (284)
Lymphoma (136)
Machine learning (6)
Management (31)
Manufacturing (276)
MASH (62)
Medical device (13797)
Medtech (13801)
Mergers & acquisitions (16514)
Metabolic disorders (589)
Multiple sclerosis (72)
NASH (11)
Neurodegenerative disease (73)
Neuropsychiatric disorders (16)
Neuroscience (1621)
NextGen: Class of 2025 (5757)
Non-profit (3985)
Now hiring (21)
Obesity (300)
Opinion (154)
Ovarian cancer (72)
Pain (81)
Pancreatic cancer (82)
Parkinson's disease (131)
Partnered (19)
Patents (207)
Patient recruitment (103)
Peanut (40)
People (50233)
Pharmaceutical (33)
Pharmacy benefit managers (19)
Phase I (16108)
Phase II (23146)
Phase III (17898)
Pipeline (1172)
Policy (128)
Postmarket research (1989)
Preclinical (6102)
Press Release (67)
Prostate cancer (102)
Psychedelics (28)
Radiopharmaceuticals (225)
Rare diseases (303)
Real estate (4971)
Recruiting (40)
Regulatory (19559)
Reports (26)
Research institute (2100)
Resumes & cover letters (187)
Rett syndrome (5)
RNA editing (3)
RSV (31)
Schizophrenia (64)
Series A (108)
Series B (67)
Service/supplier (16)
Sickle cell disease (45)
Special edition (11)
Spinal muscular atrophy (121)
Sponsored (28)
Startups (2845)
State (2)
Stomach cancer (10)
Supply chain (67)
Tariffs (23)
The Weekly (21)
Vaccines (525)
Venture capitalists (24)
Weight loss (194)
Women's health (30)
Worklife (10)
Date
Today (186)
Last 7 days (756)
Last 30 days (2522)
Last 365 days (27859)
2025 (9777)
2024 (30129)
2023 (34606)
2022 (44674)
2021 (48270)
2020 (47675)
2019 (41917)
2018 (31723)
2017 (27696)
2016 (26534)
2015 (30542)
2014 (23019)
2013 (19210)
2012 (20890)
2011 (21566)
2010 (19803)
Location
Africa (590)
Alabama (38)
Alaska (5)
Arizona (176)
Arkansas (12)
Asia (35246)
Australia (6748)
California (5090)
Canada (1881)
China (486)
Colorado (242)
Connecticut (261)
Delaware (147)
Europe (73524)
Florida (847)
Georgia (175)
Hawaii (1)
Idaho (52)
Illinois (517)
India (27)
Indiana (268)
Iowa (5)
Japan (158)
Kansas (85)
Kentucky (23)
Louisiana (11)
Maine (57)
Maryland (822)
Massachusetts (3675)
Michigan (157)
Minnesota (328)
Mississippi (2)
Missouri (78)
Montana (23)
Nebraska (22)
Nevada (64)
New Hampshire (65)
New Jersey (1580)
New Mexico (22)
New York (1496)
North Carolina (912)
North Dakota (7)
Northern California (2235)
Ohio (196)
Oklahoma (12)
Oregon (26)
Pennsylvania (1258)
Puerto Rico (13)
Rhode Island (28)
South America (894)
South Carolina (23)
Southern California (1919)
Tennessee (97)
Texas (820)
United States (19989)
Utah (166)
Virginia (141)
Washington D.C. (55)
Washington State (486)
West Virginia (3)
Wisconsin (51)
566,436 Results for "concord medical services holdings limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Concord Medical Files 2023 Annual Report on Form 20-F
Concord Medical Services Holdings Limited today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 (the “Annual Report”) with the U.S. Securities and Exchange Commission.
April 19, 2024
·
1 min read
Policy
Concord Medical Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price
Concord Medical Services Holdings Limited announced that it has received a letter from the New York Stock Exchange dated February 12, 2024, notifying the Company that it is below compliance standards due to the trading price of the Company’s American depositary shares and that the applicable cure period for the Company to regain compliance expires on August 12, 2024.
February 20, 2024
·
3 min read
Business
Concord Medical Reports Financial Results for the First Half of 2023
Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2023.
September 22, 2023
·
15 min read
Press Releases
ITF Therapeutics LLC Announces Opening of New U.S. Headquarters in Concord, Massachusetts
March 5, 2025
·
6 min read
Press Releases
Cuprina Holdings (Cayman) Limited Announces Pricing of $12 million Initial Public Offering
May 6, 2025
·
4 min read
Press Releases
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
April 14, 2025
·
5 min read
Press Releases
Concord Healthcare Announces Approval Granted to the Application for the Proton Therapy Equipment Registration Certificate
December 9, 2024
·
3 min read
Press Releases
Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment
September 16, 2024
·
3 min read
Press Releases
Concord Medical Regains Compliance with NYSE Minimum Price Requirement
August 7, 2024
·
2 min read
Business
CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE
July 15, 2024
·
3 min read
1 of 56,644
Next
